CO4940458A1 - Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo - Google Patents

Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo

Info

Publication number
CO4940458A1
CO4940458A1 CO98034144A CO98034144A CO4940458A1 CO 4940458 A1 CO4940458 A1 CO 4940458A1 CO 98034144 A CO98034144 A CO 98034144A CO 98034144 A CO98034144 A CO 98034144A CO 4940458 A1 CO4940458 A1 CO 4940458A1
Authority
CO
Colombia
Prior art keywords
hydrogen
farnesilo
alkyl
protein transferase
independently selected
Prior art date
Application number
CO98034144A
Other languages
English (en)
Spanish (es)
Inventor
W Remiszewski Stacy
Alan K Mallams
Original Assignee
Scherign Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherign Corp filed Critical Scherign Corp
Publication of CO4940458A1 publication Critical patent/CO4940458A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO98034144A 1997-06-17 1998-06-16 Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo CO4940458A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
CO4940458A1 true CO4940458A1 (es) 2000-07-24

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98034144A CO4940458A1 (es) 1997-06-17 1998-06-16 Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo

Country Status (14)

Country Link
EP (1) EP0989979A1 (https=)
JP (1) JP2002506444A (https=)
KR (1) KR20010013881A (https=)
CN (1) CN1267291A (https=)
AR (1) AR013094A1 (https=)
AU (1) AU8253598A (https=)
CA (1) CA2293706C (https=)
CO (1) CO4940458A1 (https=)
HU (1) HUP0002954A3 (https=)
IL (1) IL133389A0 (https=)
NZ (1) NZ501571A (https=)
PE (1) PE82799A1 (https=)
WO (1) WO1998057948A1 (https=)
ZA (1) ZA985205B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2904393A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
JP2001500508A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な置換ベンゾシクロヘプタピリジン誘導体
ES2234036T3 (es) * 1996-09-13 2005-06-16 Schering Corporation Compuestos utiles para inhibir la farnesil-protein-transferasa.

Also Published As

Publication number Publication date
HUP0002954A3 (en) 2002-11-28
AU8253598A (en) 1999-01-04
JP2002506444A (ja) 2002-02-26
PE82799A1 (es) 1999-08-26
KR20010013881A (ko) 2001-02-26
NZ501571A (en) 2002-02-01
HUP0002954A2 (hu) 2001-06-28
ZA985205B (en) 1998-12-15
IL133389A0 (en) 2001-04-30
EP0989979A1 (en) 2000-04-05
CN1267291A (zh) 2000-09-20
WO1998057948A1 (en) 1998-12-23
CA2293706C (en) 2008-11-18
CA2293706A1 (en) 1998-12-23
AR013094A1 (es) 2000-12-13

Similar Documents

Publication Publication Date Title
CO4940458A1 (es) Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
TR199802136T2 (xx) �MPDH enzimi inhibit�rleri olarak �re t�revleri.
ES2144421T3 (es) Nuevo derivado tetrapeptidico.
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
NO20044807L (no) Heratitt C virus inhibitorer
ATE404538T1 (de) Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität
CO5611143A2 (es) Profarmacos de fosfatos de fluorooxindoles
DE69420564D1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton
NO874549D0 (no) Sulfonperoxycarboxylsyrer, deres anvendelse for blekning og preparater inneholdende samme.
DE69334199D1 (de) Vasopressin antagonist und oxytocin antagonist
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
AR017019A1 (es) Compuestos derivados del 2-(4-aril o heteroarilpiperazin-1-ilmetil)-1h-indol, composiciones y su uso en la manufactura de medicamentos
UY24010A1 (es) Nuevos pirrolocarbazoles
NO985335L (no) 2,4-Diaminopyrimidinderivater
DK39286D0 (da) Imidazolderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse derivater
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
NO961236L (no) Pyrrolodiazin-derivater som stabilisatorer for klorholdige polymerisater
TW200407325A (en) Novel interleukin-1β converting enzyme inhibitors
AR012990A1 (es) Compuestos de benzo(5,6) cicloheptapiridina, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos como inhibidores de laproteina farnesil transferasa.
CO4940475A1 (es) Novedosos inhibidores de sulfonamida de la farnesil-protein transferasa
EA200200727A1 (ru) Новые производные индола
AR012730A1 (es) Compuestos derivados de aminocicloalquilpirrolidina sustituida cis-sustituidos, droga, agente antimicrobiano y compuesto intermediario
PL352172A1 (en) Derivatives of n-alkoxyalkylo-n,n-dialkyloamine or salts thereof and the agents containing these compounds used in treatment of neurodegenerative diseases
ES2106439T3 (es) 5-(piperazinilalquil)-1,5-benzotiazepinonas utiles como antagonistas de calcio.